钠-葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病合并心力衰竭研究进展

Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus with Heart Failure

心力衰竭是2型糖尿病心血管疾病的相关表现之一,也是该人群住院的主要原因之一。因此,能够降低心力衰竭风险的药物治疗尤其具有吸引力。钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂可降低2型糖尿病患者的心力衰竭风险,但其作用机制不十分明确。现对SGLT-2抑制剂的研究进展、作用机制及临床应用进行总结,以期为2型糖尿病合并心力衰竭治疗提供新思路。

Heart failure is one of the manifestations of cardiovascular disease in type 2 diabetes mellitus(T2DM),and it is also one of the main causes of hospitalization in this population.Therefore,the medications that can reduce the risk of heart failure are particularly attractive.Sodium-glucose cotransporter 2(SGLT-2)inhibitors can reduce the risk of heart failure in patients with T2DM,but its mechanism is not very clear.This paper summarizes the mechanism and clinical application of SGLT-2 inhibitors in order to provide new ideas for the treatment of patients with T2DM and heart failure.